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RESUMO – Racional - A despeito da sua relativa raridade, o adenocarcinoma de 
vesícula biliar é neoplasia que apresenta comportamento biológico agressivo. O 
único tratamento curativo tem sido a ressecção cirúrgica radical com margem livre. 
Fatores prognósticos têm sido estudados por serem importantes para identificar 
pacientes que podem se beneficiar de ressecção cirúrgica agressiva.  Objetivo 
- Avaliar preditores prognósticos em longo prazo de pacientes com câncer da 
vesícula biliar. Métodos - Foram identificados e retrospectivamente revisados 
os prontuários médicos de todos os doentes submetidos a tratamento cirúrgico 
que apresentavam diagnóstico histológico confirmado de adenocarcinoma 
de vesícula biliar durante período de 14 anos. Os dados foram submetidos à 
análise estatística uni e multivariada. Resultados - A amostra total foi de 100 
doentes. A mediana de idade foi de 71 anos (34 a 93). Houve 17 mulheres e 83 
homens. A distribuição das lesões de acordo com o sistema de estadiamento 
TNM foi: I (n=22), II (n=59), III (n=6), IV (n=4) e desconhecido (n=9). Cinquenta 
e dois doentes foram submetidos à ressecção radical (R0) enquanto 48 à cirurgia 
paliativa (R1-R2). A morbidade global foi de 14% enquanto que a mortalidade 
pós-operatória (até 30º dia do pós-operatório) foi de 12 %. A taxa de sobrevida 
em cinco anos foi de 28% enquanto a mediana de sobrevida foi de 10 meses. A 
análise multivariada identificou seis fatores prognósticos: estádio T, nível sérico 
de CA 19.9, perfuração da vesícula biliar, embolização linfática, coorte cirúrgico 
histórico e linfadenectomia hilar. Conclusão - O tratamento do câncer de vesícula 
biliar apresenta alta morbimortalidade. Os fatores prognósticos foram: estádio T, 
nível sérico de CA 19.9, perfuração da vesícula biliar, embolização linfática, coorte 
cirúrgico histórico e linfadenectomia hilar.
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ABSTRACT – Background – In spite its relative rarity, gallbladder adenocarcinoma 
is a neoplasm who presents an aggressive biologic behavior. The single curative 
treatment has been radical surgical resection with free margin. Prognostic 
factors has been studied because are very important to identify long-term 
survival patients which may benefit of aggressive surgical resection. Aim - To 
evaluate long-term prognostic predictors from gallbladder cancer. Methods - The 
medical records of all patients that presented confirmed histological diagnosis of 
gallbladder adenocarcinoma operated over a 14 year period were identified and 
retrospectively reviewed. Uni and multivariate analysis was done. Results - Total 
sample was 100 patients. Median age was 71 years (34 to 93). There were 17 men 
and 83 women. Lesion distribution according to TNM stage system was: I (n=22), II 
(n=59), III (n=6), IV (n=4) and unknown (n=9). Fifty two patients underwent radical 
resection (R0) while 48 to palliative surgery (R1-R2). Overall major morbidity was 
14%, while postoperative surgical mortality rate (30th postoperative day) was 
12 %. Five-year survival rate was 28% while median of survival was 10 months. 
Multivariate analysis identified six prognostic factors: T stage, serum level of CA 
19.9, gallbladder perforation, lymphatic embolization, surgical historical cohort 
(after 2002) and hilar lymphadenectomy. Conclusion - Prognostic factors were: 
T stage, serum level of CA 19.9, gallbladder perforation, lymphatic embolization, 
surgical historical cohort and hilar lymphadenectomy.
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INTRODUCTION
Gallbladder carcinoma (GBC) is the most common malignant biliary neoplasm and the 7th most common gastrointestinal 
cancer20. Tumor resection with free margins remains 
curative therapy. Nevertheless GBC at an early stage 
may be cured by simple cholecystectomy. Generally 
it is diagnosed at an advanced stage, when major 
resections including hepatectomy should be necessary 
for attaining free margins4,5,8,11,12,20. Although safety 
of these surgical procedures has improved over last 
years – due to major advances in both operative and 
perioperative management -, the overall mortality for 
advanced GBC remains high, when compared with 
other gastrointestinal surgeries9,10,11. Generally, it is 
more commonly found in elderly patients with several 
clinical comorbidities. Furthermore the outcome 
of patients with advanced disease requiring major 
resection is dismal1,13,25. Prognostic factors have been 
studied such as epidemiology/demography (age, 
gender), management treatment (radical operative 
procedures, adjuvant therapy) and histological 
(TNM stage, grade, perineural or vascular-lymphatic 
embolization). These prognostic factors along the 
time had represented the most important predictors 
of GBC in long follow-up3,4,10,11,12,14,21,22,23,24,25.
The aim of this study was to identify prognostic 
factors in long-term survival in GBC in Brasil.
METHODS
A retrospective analysis of the prognostic factors 
in 100 patients treated at São Paulo Francisco Morato 
de Oliveira Hospital – HSPE-FMO with confirmed 
histological diagnosis of gallbladder adenocarcinoma 
was performed. The study period was between January 
1995 and January 2009. This study was approved by 
ethic committees of both HSPE-FMO and Federal 
University of São Paulo. All patients were identified 
from both HSPE-FMO cancer registry and Department 
of Pathology.
Only adenocarcinomas histologically proven 
were included. Only underwent surgical treatment 
patients were considered to the final analysis. Patients 
who underwent both radical (R0) and palliative surgery 
(R1-R2) were included. Preoperative metastatic 
disease was also excluded. Information extracted to 
find possible long-term prognostic factors were: 1) 
demographics data (age, sex, ethnicity, MCI, ASA, pre-
operative diagnosis, incidental diagnosis, historical 
surgical cohort); 2) laboratory analysis (serum levels 
of bilirrubins, albumin and tumor markers); 3) surgical 
treatment (type of surgery, previous surgery, surgical 
time, blood loss, transfusions, morbidity); 4) histology 
(localization, status of the surgical margins, TNM 
stage, macroscopic type, grade, lymphatic or vascular 
embolization, perineural invasion, inflammatory 
process, gallbladder perforation or necrosis); 5) 
adjuvant treatment. 
Sixth edition of the AJCC TNM staging 
manual was employed. The types of surgery were 
simple cholecystectomy or partial hepatectomy 
(bisegmentectomy IV-V or right hepatectomy). When 
hilar lymphadenectomy (HL) was indicated, resection 
of porta hepatis and supraduodenal nodes were 
performed (N1). If N2 nodes were suspected, additional 
lymphadenectomy was done. Bile duct resection was 
performed only if there were bile duct invasion or even 
the surgical margin was close. Reconstruction with 70 
cm Roux-en-Y biliary enteric bypass was performed 
when bile duct resection was done. Completeness 
of resection was classified as R0, R1 or R2 always 
depending on the margin status and intraoperative 
impression of the surgical team that were confirmed 
in definitive histological analysis. R0 was defined as no 
residual disease, R1 as microscopically positive margin 
and finally R2 as macroscopically residual disease. 
All of the hepatectomies were performed by senior 
oncology surgeon team.
Overall survival was measured from the day of 
operation to death, including cancer death and other 
causes, and to the last day of follow-up considered so 
until last medical return or death. 
Survival curves were estimated using the Kaplan-
Meier method and compared using log-rank test. Cox 
regression analysis was carried out to determine which 
factors were the best prognostic determinants. P< 
0,05 was considered statically significant. All statistics 
analyzes were performed using SPSS 17.0 software 
(SPSS-USA).
RESULTS
One hundred sixteen GBC patients were identified. 
However, 16 patients were excluded due uncompleted 
records (n=14) and no-adenocarcinoma (n=2) at histology. 
Consequently, 100 patients who underwent surgical 
resection were the aim of the present study (Table 1). 
The distribution of the gender was: 83 females 
(83%) and 17 males (17%). Median age was 71 years 
(34 to 93), while mean age was 69 years. Ninety 
five patients were caucasians and five no. Fifty four 
presented associated diseases: systemic arterial 
hypertension (n=47), diabetes (n=12), coronary 
insufficiency (n=3), congestive cardiac insufficiency 
(3), mental demency (n=2), renal chronic insufficiency 
(n=1), and sclerodermia (n=1). The BMI was 27.8 
ranging from 18 to 43. The ASA classification showed 
46 patients in ASA 1, 30 in ASA II and 21 in ASA III. The 
clinical findings were: jaundice in 42 patients, acute 
cholecistitis in 36, weight loss in 21, acute cholangitis 
in six and acute pancreatitis in one patient. The mode 
of presentation was: incidental finding in 63 patients, 
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localized mass (advanced lesion) in 37. The laboratory 
findings were: bilirrubines (ng/dl) 0,7 (0,2-28), albumin 
(ng/dl) 3,5 (1,3-4,7), ACE (ng/dl) 4,5 (0,2-535) and  CA 
19.9 (ng/dl) 35,6 (1,2-24150).
Were done 52 hepatectomies (21 with en-bloc 
biliary resection plus biliary reconstruction) and 48 
simple cholecystectomies. Fourty seven operations 
were bisegmentectomy IV + V, while five right 
hepatectomies. There were 73 elective surgeries 
while 27 patients were operated in emergency 
situation due to complications of their gallstone 
disease. Seven patients underwent some type of hilar 
lymphadenectomy. There were 52 R0 resections and 48 
in R1-R2. Overall morbidity was 46%, in which 14 had 
major complications (14%) that needed reoperation 
during their hospital stay. Overall postoperative 
mortality (30 days) was 12%. Elective surgery mortality 
was 5%. All patients submitted to emergency surgery 
to treat acute cholangitis (n=6) died due infectious 
complications. Overall mortality rate of the first period 
(cohort before 2002) was 25 % while in second period 
(cohort after 2002) was 3,3%. 
Surgical treatment characteristics were: simple 
cholecistectomy in 48 patients, resection of segments 
IV + V in 47, formal right hepatectomy in five, bile duct 
resection + biliary bypass in 21, hilar lymphadenectomy 
in 70, multivisceral resection in four and biliary bypass 
in six patients. 
The surgical findings were: median operative 
time (min): 185 (58-510);  median operative bleeding 
(ml): 400 (0-4000); median hospital stay (days): 18 (1-
75); major morbidity: 14 (14%); reoperation: 14 (14%) 
and overall mortality: 12 (12%).
Seventeen patients (17%) underwent adjuvant 
treatment (radiotherapy or/and chemotherapy). 
Histological characteristics are shown in Table 1. 
Fifty six patients presented documented 
tumor recurrence distributed as:  multiple (two sites 
minimum)=29, peritoneum=14, liver=10, lymph 
nodes=2, biliary system=1. Nineteen patients 
presented no recurrence in 40 months median follow-
up period (5 to 120 months). Median survival time 
was 10 months, while de 5-year survival was 28%. The 
Kaplan-Meier curve is shown on Figure 1A. 
Analysis of prognostics factors 
Twenty nine variables were analyzed related 
to possible prognostic factors in this sample. On 
univariate analysis, it was found that T-stage, no 
billiary resection, radicality (R1), blood transfusions, 
CA 19.9>40 ng/dl, bilirrubines>4 ng/dl, gallbladder 
perforation, tumor grade, lymphatic embolization, 
surgical cohort<2002, obesity, TNM classification, 
no fundic location, positive lymph node, and 
reoperation due postoperative complication were 
statically significant factors for dismal survival 
(Table 2).
On multivariate analysis, were identified as 
TABLE 1 - Histological characteristics (n=100)
Number of patients 100
Grade tumor
      I                                                                                                         33
      II/III 77
Tumor-stage
      T1 6
      T2 24
      T3 66
      T4 4
Clinical stage (TNM)
       I                                                                                                                            22
      II 59
      III 6
      IV 4
      No-defined 9
Macroscopic findings
Local of the lesion
      Fundus 31
      Neck 8
      Infundibulum 26
      Difuse    35
Macroscopic type
      Papilifer-fungoid     13
      Nodular 23
      Infiltrative 40
      No especific 24
Microscopic findings
      Perineural invasion                                                      57
      Vascular invasion 45
      Lymphatic embolization 58
      Peri-tumoral inflamation                        34
      Necrosis 42
      Gallbladder perfuration 41
Lymph nodes
      No 43
      N1 48
      Nx 9
TABLE 2 -  Univariate analysis  
Variable P Odds Ratio (Exp B)
IC 95% to Exp (B)
 Inferior Superior
 T-stage , 092 6.238 , 743 52.357
 Age , 120 , 944 , 877 1.015
 Gender , 240 , 357 , 064 1.993
 Body mass index , 172 , 829 , 633 1.085
 Hepatectomy , 639 , 626 , 088 4.436
 Pre-operative diag , 075 , 135 , 015 1.223
 Bile duct resection. , 966 1.036 , 203 5.297
 Radicality (R0/R1) , 031 6.078 1.183 31.216
 Blood transfusions , 166 3.800 , 575 25.099
 CA19.9>40 , 000 233.063 13.884 3912.330
 Antigen carcinoembrionary>20 , 014 , 083 , 011 , 604
 Bilirrubines>04 , 026 8.846 1.293 60.535
 Albumine<3 , 173 , 289 , 048 1.727
 Gallbladder necrosis , 047 , 009 , 000 , 933
 Gallbladder perfuration , 147 38.261 , 279 5247.573
 Grade , 847    
 Grade (1) , 614 1.969 , 141 27.509
 Grade (2-3) , 826 , 806 , 117 5.531
 N-stage , 130 , 226 , 033 1.547
 Lymphatic embolization , 002 506.393 9.904 25892.924
 Perineural invasion , 013 , 018 , 001 , 421
 Inflammatory reaction , 002 , 033 , 004 , 287
 Surgical time>80 , 261 , 353 , 057 2.171
 Surgical cohort<2002 , 001 29.134 3.883 218.596
 Colestasis , 059 , 053 , 003 1.113
 Obesity , 036 37.305 1.267 1098.629
 UICC-TNM , 798 1.586 , 046 54.316
 Gallbladder localization  
(fundus or no) , 694 1.570 , 165 14.914
 Lymphadenectomy , 000 255.652 15.398 4244.538
 Reoperation , 029 11.043 1.272 95.878
 Adjuvant treatment , 007 , 020 , 001 , 338
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significant independent prognostic factors (Table 
3): survival time and T–stage (Figure 1A and 1B), 
CA 19.9 >40,0 ng/dl and gallbladder perforation 
(Figure 2A and 2B), lymphatic embolization and 
surgical cohort<2002 (Figure 3A and 3B) and, finally, 
no lymphadenectomy (Kaplan-Meier according hilar 
lymphadenectomy: positive=28% in 5-years (median 
of survival time=12,0 months) X negative=26% in 
5-years (median of survival time=7,0 months).
FIGURE 1 - A) Kaplan-Meier curve of cumulative overall 
survival time (n=100):  28% in 5-years (median 
of survival time: 10,0 months - IC 95%: 6,6 to 
13,3 months); B) Kaplan-Meier curves of the 
100 patients undergoing resection of GBC by 
T–stage (TNM-UICC): T1=75% - 5-years (n=6), 
T2=51% - 5-years (n=24),  T3=18% - 5-years 
(n=66), T4=5% - 1-year (n=4)
FIGURE 2 -A) Kaplan-Meier curves by serum level of CA 
19.9: < 40ng/dl=62% - 5-years X  CA19.9>40 
ng/dl=7,8% in 5-years; B) Kaplan-Meier curves 
by gallbladder perforation: negative=46% 
in 5-years (median of survival time=18,0 
months) X  positive=0% in 5-years (median of 
survival time=7,0 months)
TABLE 3 -   Multivariate analysis – logistic regression   
P Odds Ratio (Exp B)
IC 95% to Exp (B)
Inferior Superior
  T stage 0.005 2.759 1.364 5.579
 CA 19.9 (> 40ng/dl) 0.000 6.386 2.630 15.506
 Gallbladder perfuration 0.005 3.082 1.412 6.723
 Lymphatic embolization 0.038 2.923 1.058 8.075
 Surgical cohort (<2002) 0.000 5.477 2.229 13.460
 Lymphadenectomy 0,0027 3.624 1.156 11.362
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DISCUSSION
Few studies have been reported about prognostic 
factors in GBC. Perhaps, because it is relatively rare 
tumor found on occidental countries (except some 
areas as Chile, Bolivia, Mexico, and east Europe) few 
studies has been conducted in Occident.
Real knowledge of the prognostic factors could 
lead to make a therapeutic decision that could 
avoid expensive costs. It could save patients of the 
unnecessary large surgical procedure. For example, 
in oriental countries as Japan, all efforts have been 
done to perform ultra-radical operations (extended 
surgeries) for treating advanced GBC. Even there 
surgery carried high morbidity, high mortality rates and 
poor outcome. Radical resection seems to be limited 
in patients with advanced GBC. Thus with adequate 
selection, referential centers can treat advanced GBC 
with radical surgery identifying  the prognostic factors 
to select the patients1,3,5,7,10,11,14,19,20,21,22,23,24,25.
Although, simple cholecystectomy seems to 
be enough for treating GBC restricted to mucosa 
(T1a), radical surgery with hepatic resection and hilar 
lymphadenectomy has been considered the gold 
standard therapeutic choice in more advanced stages 
( T1b-T3 or few T4). Despite great rates of specific 
surgical complications, these extended procedures are 
the single option to cure. 
Though overall mortality has been decreased 
in recent studies, the morbidity seems high1,2,3,4,5,6,7,8,9
,10,11,12,13,14,15,16,17,18,19. In according with Chan et al.4, the 
overall postoperative mortality with radical surgery 
for gallbladder cancer ranged 1% to 8,3%. The overall 
mortality of the present study (to the elective surgery) 
of 5,7% is similar to the one found in the literature. 
More recently, Pais-Costa et al.16,17 shown in two small 
series of selected T2 and T3 GBC patients submitted 
to hepatectomy, 0% of the mortality rate in Brazil. 
Nevertheless, the high morbidity seems still stable; it 
has ranged among 12% and 33% in different series1,2,3,4
,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21.Major morbidity was similar 
to recent reports4. Concomitantly, extended procedure 
series improved in reports over recent years4,19,20. Like 
Konstantinidis et al.12, was observed a significant 
improve in hepatectomy aiming GBC treatment on 
recent years. Before 2002 only 17 hepatectomies 
were performed versus 37 hepatectomies after 2002. 
Therefore with improve of the experience on enlarged 
resection associated to decrease of overall mortality, 
has been observed major freedom to indicate more 
frequently extended resections in Brazil16,17.
Median survival time in present series was 
low (10 months), perhaps due to high mortality of 
emergency surgeries; similar results had Duffy et al.8 as 
Liang et al.21. Overall 5-year survival rate of 28 % was 
comparable with recent studies (26% and 35%12,13,14,23).
Previous reports identified many prognostic 
factors. They were: age, gender, jaundice, depth 
of invasion, hepatic invasion, bile duct invasion, 
hepatoduodenal ligament invasion, lymph node 
metastasis, distant metastasis, residual disease, 
type of surgery (R0, R1 and R2), type of diagnosis 
(incidental or no), lymphadenectomy, perineural 
invasion, vascular invasion, lymphatic invasion, grade 
of differentiation4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19.
Like other authors, these authors preferred to 
exclude patients with distant metastasis considering 
that no therapeutic surgery should be done in these 
FIGURA 3 - A) Kaplan-Meier curves by lymphatic 
embolization: negative=57% in 5-years X 
positive=7% in 5-years; B) Kaplan-Meier 
curves by historical surgical cohort: after 
2002=41% in 5-years ((median of survival 
time=18,0 months) X before 2002=10% in 
5-years (median of survival time=6,0 months)
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situations8. T stage has been described with a strong 
predictor of long-term survival for many tumors. 
Basically, deep invasion of gallbladder layer is the most 
valuable predictor of both loco-regional and systemic 
dissemination. This observation was evident in this 
study, where survival time was significantly decreased 
with an increase of the T stage. The 5-year survival time 
was 75% to the T1 versus 51% and 18% respectively 
to the T2 and T3 stages. Only 25% of the T4 patients 
survived one year (median of three months). Recently, 
in China, Liang et al.13 observed that T stage was the 
strongest survival predictor. These authors shown that 
for T1 tumors the 5-year survival was 100% against 78% 
for T2 and only 17% for T3 (p<0,000). Kayahara et al.11 
in a large multicentre study of 4770 patients in Japan 
observed that TNM stage was the strongest long-term 
predictor at multivariate analysis (p<0.0001). T stage 
also increases probability of lymph node disease. This 
paper observed that lymph nodes were respectively 
comprised on 0% at T1, 33% at T2 and 57% at T3 stages, 
similarly to other authors in literature4,7,9.
Nevertheless, lymph node metastasis has been 
considered predictor of dismal prognosis for patients 
with advanced GBC7,14,21, here no association was 
found. Perhaps, when multivariate analysis was done 
lymphatic invasion could be one confused variable at 
logistic regression. Like recently described by Shibata 
et al.24 was observed that lymphatic embolization was 
one independent prognostic factor at multivariate 
analysis. Controversies have remained about role of 
the lymphadenectomy for treating GBC. Few Western 
reports have found node positive long-term survivors 
who underwent hilar lymphadenectomy. For example, 
Benoist et al.2 advocated that radical resection should 
only be performed if there are no comprised loco-
regional nodes. On the contrary, Japanese school 
has shown an improvement of the overall prognosis 
in patients which underwent lymph node dissection 
when lymph node metastasis were limited to the lymph 
nodes within the hepatoduodenal ligament14,21.  Like 
other gastrointestinal cancers, controversies about 
the aim of the lymphadenectomy seem difficult to 
solve. Similarly to Japanese studies, was here observed 
improvement of the overall prognosis in patients 
which hilar lymphadenectomy even with compromised 
nodes.  Perhaps, this finding could favor the therapeutic 
role of the systematic lymphadenectomy. Hilar 
lymphadenectomy has been considered important as 
prognosis in adjuvant treatment. In the present study, 
like in Sakata et al.21 paper, hilar lymphadenectomy was 
found independent prognostic factor for long-term 
survival. This fact could also explain that there was no 
significance in node positive as independent prognostic 
factor. Therefore, the authors of this study think that 
it could present therapeutic potential role, as far as 
hilar lymphadenectomy was considered independent 
prognostic variable at multivariate analysis. 
Although CA 19.9 has been associated with 
prognosis in other gastrointestinal cancers - mainly 
colorectal cancer -, the real prognostic value of the 
serum levels of the CA 19.9 to the GBC remains 
unclear. Few studies associated serum levels of the CA 
19.9 with prognosis of resectable GBC. Hatazaras et 
al.9 observed that the value of CA 19.9>35 ng-dl was 
the single significant long-term prognostic factor to 
the billiary tumors. They observed a very low long-
term survival in the patients who underwent a radical 
surgery but preoperative levels of CA 19.9 were higher 
than 35 ng/dl (15.1 months X 67.4 months). In this 
paper was observed a poor long-term prognosis in 
patients presenting high preoperative serum levels of 
the CA 19.9 (>40 ng-dl).  When it was higher than 40 
ng/dl was found dismal overall prognosis.
In general lines, tumor perforation could lead 
peritoneal dissemination worsening overall long-term 
prognosis. This question has been discussed mainly 
in colorectal cancer18. In present study, gallbladder 
perforation showed worse prognosis, with seven 
months of median of survival time. More recently, 
occidental school has treated GBC by more aggressive 
surgical procedures8,12,19,20. Initially, occidental surgical 
institutions thought that radical resection of GBC with 
extended surgeries was not effective because the 
dismal prognosis independently of major resections 
for treating this neoplasm15,20. However, in this study 
neither hepatectomy nor R0 surgery were independent 
prognostic factors, although the second surgical cohort 
(after 2002) had presented better prognosis than first 
one (before 2002). More proportionally numbers of 
hepatectomies were performed in second period (3:1). 
Possibly, best long term survival has been obtained 
with more radical surgeries like previously published 
studies10,25. Kostatinidis et al.13 observed in four historic 
moments that there was an improving of the overall 
survival with more radical surgery performed in recent 
periods. This paper observed proportionality in radical 
surgery with hepatectomy and hilar lymphadenectomy 
after 2002. Additionally, the second historical cohort 
(after 2002) was an independent prognostic factor for 
long-term survival at multivariate analysis. This fact 
has also been confirmed in more recent occidental 
studies8,12,19,20. 
CONCLUSION
Prognostic factors were: T stage, serum level of CA 
19.9, gallbladder perforation, lymphatic embolization, 
surgical historical cohort and hilar lymphadenectomy. 
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